ObjectiveTo investigate the clinical effect of Xiaoer Dingchuan oral liquid combined with budesonide suspension aerosol inhalation for children with cough variant asthma. MethodsA total of 124 children with cough variant asthma who were treated in our hospital from May 2017 to June 2019 were selected as the research objects. The random number method was employed to assigned patients to two groups, with 62 cases in each group. On the basis of conventional treatment, the control group was treated with budesonide suspension aerosol inhalation, based on which the observation group was additionally administered Xiaoer Dingchuan oral liquid, for a one-month treatment course. Clinical efficacy, inflammatory factors levels, immunoglobulin levels, and adverse reactions were compared between the two groups. ResultsAfter 1 month of treatment, the total effective rate (87.1%) of the observation group was significantly higher than that of the control group (71.0%), with a statistically significant difference (P＜0.05). The interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α) and interleukin-8 (IL-8) levels in the two groups significantly decreased, and the levels in the observation group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). The serum immunoglobulin IgM, IgG and IgA levels in the two groups significantly increased, and the levels in the observation group were significantly higher than those in the control group, with statistically significant differences (P＜0.05). During treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionXiaoer Dingchuan oral liquid combined with budesonide suspension aerosol inhalation for children with cough variant asthma can significantly improve the clinical efficacy, decrease the level of inflammation, improve the immunity of children, and thus it is highly safe.

无